Humanin Research Guide: Mitochondrial-Derived Peptide, Neuroprotection, and Longevity Research

By Justin Cartier

Humanin is a small peptide coded by a mitochondrial gene. Research keeps coming back to it for two reasons. It protects cells from dying, and it ties into longer, healthier aging.^[1] It was first spotted in brain cells that somehow survived in Alzheimer’s disease tissue. The peptide blocks a cell-death protein called BAX. It also shields neurons from amyloid-beta, the toxic protein linked to Alzheimer’s.^[1] Humanin levels in the blood fall as we age. In animal and lab studies it also improves how the body handles insulin.^[4]

Research-use note: Humanin is a research compound, not a medicine. Everything below is for laboratory research and education only, not human use.

What is humanin and how was it discovered?

Humanin turned up in an unexpected place. It was found in brain cells that stayed alive in Alzheimer’s disease tissue, while the cells around them were dying off.^[1] Researchers traced its code back to the mitochondrial 16S ribosomal RNA gene. Nobody thought that stretch of the genome made proteins at all. The peptide encoded there blocks BAX-driven cell death in neurons exposed to amyloid-beta.^[1][2] That made humanin the first mitochondrial-derived peptide, or MDP, ever found in the context of brain protection.

This turned out to be no fluke. Cobb and colleagues, in the journal Aging, showed humanin and its related mitochondrial-derived peptides shift with age. They also help govern cell death, insulin response, and inflammation.^[3] That link between a mitochondrial peptide and human aging is exactly what pushed humanin into serious aging research, right alongside MOTS-c and the other MDPs.

How the humanin peptide works

It works through a few paths at once, and the headline one is blocking cell death. Humanin binds the protein BAX directly and stops it from punching holes in the mitochondrial membrane. That shuts down the built-in self-destruct pathway in neurons and heart cells.^[2] On top of that, it switches on STAT3 signaling, which helps cells survive and shapes both metabolism and inflammation. It also binds a cell-surface receptor, the formyl peptide receptor FPRL1/FPR2, found on immune cells and neurons. That receptor drives a good chunk of its anti-inflammatory and metabolic effects.^[3]

Put those together and they add up to one thing. Cells under stress simply survive better when humanin is around. In animal models the size of the effect tracks the dose and the tissue. Neuron and heart protection are the best-studied. Insulin-sensitive tissues respond too, through that FPR2 and metabolic path.^[3]

Humanin and insulin sensitivity

It also sharpens how the body uses insulin, at least in animal studies. Muzumdar and colleagues, in PLoS One, described humanin acting as a central regulator of peripheral insulin action. It helps the body respond to insulin better.^[4] In aged rodents, giving humanin improves glucose tolerance and lowers insulin resistance. It does that partly by protecting the insulin-making beta cells from fat-related damage. The rest comes from direct signaling in muscle and liver.

Here is why that matters. Blood humanin runs lower in people with type 2 diabetes and metabolic syndrome than in healthy people the same age.^[3] Whether that low level is a cause or a consequence is still being sorted out. But the pieces fit together nicely. Humanin protects both the neurons and the beta cells that keep blood sugar steady. That would explain why its decline tracks with both brain and metabolic trouble as we age.

What diseases is humanin linked to in research?

Alzheimer’s disease is where most of the research lives. The very first paper showed humanin protects neurons from amyloid-beta by blocking that BAX-driven cell death.^[1] In mice, it also prevents age-related drops in memory. In people, higher humanin links to better cognitive aging.^[5] It is not a cure, since it does not clear existing damage. It does seem to slow the buildup and protect the neurons still standing.

Beyond the brain, humanin gets studied in heart and blood-vessel disease, metabolic syndrome, and age-related muscle loss. The common thread running through all of them is failing mitochondria. In each case the mitochondria break down in exactly the cell types where humanin is normally needed.^[3] Whether low humanin drives that damage or just marks it is still an open question.

Humanin-like peptides and analogues

Scientists have built a few humanin analogues to make it last longer or hit harder. The best-studied is HNG, or S14G-humanin. It swaps a single amino acid and comes out roughly 1,000 times stronger.^[2] Other versions include Colivelin, a humanin chimera, and the small humanin-like peptides, SHLP1 through SHLP6, made from nearby mitochondrial reading frames.^[3] Each one suits a different research question. The choice depends on the target tissue and how stable the peptide needs to be.

Comparison with other mitochondrial-derived peptides

Humanin belongs to a small family of mitochondrial-derived peptides. That family includes MOTS-c (from the 12S rRNA), the SHLPs (from the 16S rRNA), and a handful of less-studied ones.^[3] Each one flags a slightly different kind of stress. MOTS-c mostly reports energy stress and AMPK activation. The SHLPs cover cell-death signaling near humanin, and humanin itself is the most-studied protective signal of the bunch. When you compare them, factor in the target tissue. Humanin and SHLP3 favor neurons, while MOTS-c favors muscle and fat. Factor in their different receptor pharmacology too.

Safety and side effects

The safety signals from rodent studies are mild at standard research doses. The body makes this peptide naturally, so it is well tolerated across repeated-dose protocols. The reported side effects in animals are limited to mild injection-site reactions. Here is the honest caveat. The off-target risk of giving humanin or its variants is not fully mapped in long-term human studies. The human dataset is small, and no humanin-based drug has reached late-stage trials.

Dosing and routes of administration

The published research gives humanin and HNG by several routes. Those are into the belly cavity, under the skin, or into the brain ventricles, depending on the target tissue. Common rodent doses run from 0.1 to 10 mg/kg a day for whole-body studies. Brain-infusion studies use far smaller amounts, down at nanogram levels. It comes as a freeze-dried powder that you mix with bacteriostatic water before use. It has fairly limited stability at room temperature.

Regulatory and legal status

Humanin is not approved by Health Canada or the FDA for any use. So research-grade material is sold as a research chemical for laboratory use only. The legal framework and supplier criteria for buying peptides in Canada cover the details.

Documentation separates good vendors from risky ones. So buy research peptides in Canada and demand per-lot COAs.

Sourcing for research

Good sourcing comes down to documentation. Before you buy, ask the supplier a few direct questions. Does the Certificate of Analysis (COA) come from an independent third-party lab rather than the seller? Is it specific to the exact batch or lot you will receive? Does it include the real HPLC chromatogram showing purity at 98 percent or higher? Does the mass spectrometry (MS) reading match humanin’s expected mass of about 2,687 Da? That number is different for HNG and the SHLPs. For any live-animal or cell work, add endotoxin and sterility testing on top. Clear answers to all of these are the mark of a supplier worth using.

Reviv Peptides supplies humanin with a third-party COA and HPLC purity confirmation. View the Reviv Peptides shop for current availability.

Humanin peptide questions

What are the benefits of humanin peptide?

In rodent and cell research, humanin protects neurons from Alzheimer’s-type damage and improves insulin response in diabetes models. It also protects the heart in low-blood-flow injury and reduces plaque buildup in blood vessels.^[1][3] The action centers on blocking BAX-driven cell death and switching on STAT3 survival signaling.

What diseases is humanin linked to?

Alzheimer’s disease, type 2 diabetes, blood-vessel disease, low-blood-flow injury, and general aging biology.^[1][3][5] Low blood humanin tracks with worse disease in several of these.

What is the best peptide for anti-aging?

It depends on the goal. Humanin is among the strongest tools for the cell-death and mitochondrial-stress parts of aging. Other peptides like MOTS-c, epitalon, and SS-31 cover different aging hallmarks.

How does humanin peptide work?

It works through three main paths. It blocks BAX at the mitochondrial membrane to prevent cell death. It turns on cell-surface receptors that drive STAT3 survival signaling. It also improves insulin and IGF signaling, which gives the metabolic effects.^[2][3]

What are humanin-like proteins?

The small humanin-like peptides, SHLP1 through SHLP6, come from nearby mitochondrial reading frames and share overlapping activity.^[3] HNG (S14G-humanin) is a synthetic version about 1,000 times stronger than natural humanin.

Key data point: Yen and colleagues (2018, Scientific Reports) showed that humanin prevents age-related drops in memory in mice. They also showed higher humanin levels in people are linked to better cognitive aging. That is one of the clearest links yet between a mitochondrial-derived peptide and healthy brain aging.^[5]

Summary

Humanin is a mitochondrial-derived peptide that signals cell stress. It helps cells survive in the brain, in metabolic tissues, and in the heart. It is encoded by the mitochondrial 16S rRNA gene. It blocks BAX-driven cell death, switches on STAT3 survival signaling, and improves insulin response in rodent models.^[1][2][4] The published research links it to Alzheimer’s disease, type 2 diabetes, and blood-vessel disease, and its blood levels fall with age.^[3][5] No therapeutic approval exists yet. Even so, its biology is one of the cleanest examples of mitochondria-to-nucleus signaling in peptide research. For aging research, humanin is among the most useful tools in the mitochondrial-derived peptide family.

Further reading: Best peptides for anti-aging research.

Sources: [1] Humanin: rescue factor against familial Alzheimer’s disease genes and amyloid-beta (Hashimoto et al., 2001), PubMed. [2] Detailed characterization of humanin neuroprotection (Hashimoto et al., 2001), PubMed. [3] Mitochondrial-derived peptides as age-dependent regulators of apoptosis, insulin sensitivity, and inflammation (Cobb et al., 2016), PubMed. [4] Humanin as a central regulator of peripheral insulin action (Muzumdar et al., 2009), PubMed. [5] Humanin prevents age-related cognitive decline in mice and links to cognitive age in humans (Yen et al., 2018), PubMed.

Justin Cartier

The Reviv Peptides Research Team is a collective of science writers and researchers dedicated to producing evidence-based, peer-reviewed-grade content about research peptides. Our work focuses on molecular mechanisms, receptor pharmacology, and preclinical data — including GLP-1/GIP/glucagon incretin biology, growth hormone axis peptides (GHRH analogs and ghrelin-receptor secretagogues), mitochondrial-derived peptides (MOTS-c, SS-31), tissue-repair peptides (BPC-157, TB-500, GHK-Cu), and nootropic peptides (Semax, Selank). All content is written in a strict preclinical/laboratory context; none of our editorial material is intended as medical advice. Every guide is reviewed for scientific accuracy against published peer-reviewed literature.